The meaning of SEND and its importanceA Story by MedicilonSEND (Standard for Exchange of Nonclinical Data, non-clinical data exchange standard) is defined and maintained by the SEND team of the Clinical Data Inter-change Standards Consortium (CDISC). SEND isSEND (Standard for
Exchange of Nonclinical Data, non-clinical data exchange standard) is
defined and maintained by the SEND team of the Clinical Data Inter-change
Standards Consortium (CDISC). SEND is a method for collecting and presenting
nonclinical data and is one of the required standards for submitting data to
the FDA. SEND Importance According to the requirements of the US
FDA, after December 17, 2016, applications for general toxicity tests
(including single and multiple dose general toxicity tests) and carcinogenicity
tests for NDA, ANDA, and BLA must be submitted in accordance with the SEND
format standard; 2017 After December 17, 2019, general toxicity tests
(including single and multiple dose general toxicity tests) for IND
applications must also use the SEND format. Safety pharmacology trials for NDA and BLA
applications conducted after March 15, 2019, and safety pharmacology trials for
IND applications conducted after March 15, 2020, are also required to be
submitted to the FDA in SEND format. SENDIG 3.1 contains a subset of safety
pharmacology, including respiratory and cardiovascular studies. CDISC released the SEND standard SENDIG-AR
for animal regulatory studies on September 17, 2019. FDA began to support this
standard after March 15, 2020. For studies initiated after March 15, 2022,
animal regulatory research The SEND dataset is required when submitting to the
Center for Drug Evaluation and Research (CDER), depending on the type of
regulatory submission. On March 15, 2021, SENDIG-DART v1.1 was
included in the FDA catalog and is based on SEND v 3.1 for the assessment of
reproductive toxicity of antineoplastic drugs (primarily embryonic development
(EFD)). Antineoplastic drug reproductive toxicity studies are required to use
the SEND dataset for studies expected to initiate after March 15, 2023. [1].SEND | CDISC
https://www.cdisc.org/standards/foundational/send [2].https://www.fda.gov/drugs/news-events-human-drugs/send-cber-what-you-need-know-12042020 © 2023 Medicilon |
StatsAuthorMedicilonCambridge, MAAboutMedicilon is an integrated contract research organization (CRO), providing comprehensive one-stop new drug R&D services for pharmaceutical enterprises and scientific research institutions around the w.. more..Writing
|